Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Haemonetics Corp Reaffirms FY 2013 EPS Guidance; Lowers FY 2013 Revenue Guidance-Conference Call

Monday, 29 Jul 2013 07:00am EDT 

Haemonetics Corp announced that for fiscal 2014, it expects adjusted earnings per share (EPS) in the range of $2.30-$2.40 on total revenues up 7%-10% compared to 2013. The Company reported revenue of $891.99 million in fiscal 2013. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $992 million and EPS of $2.33 for fiscal 2014. 

Company Quote

-0.23 -0.64%
31 Jul 2014